


[Fig. 1]




[Fig. 2]




[Fig. 3]




[Fig. 4]


HeLa
HeLa+5AD
Cell viability (%)
120
100
80
60
40
20
0
0 0.5 1 2 12.5 25 50 (μM)
Doxorubicin
Etoposide


[Fig. 5]


Untreated
5-AD
5-AZA
Cell viability (%)
120
100
80
60
40
20
0
0 2.5 5 25 50 (μM)
Doxorubicin
Etoposide


[Fig. 6]


120
100
80
60
40
20
0
Cell viability (%)
shNC
shNC 5AD
shRIP3
shRIP3 5AD
Untreated
Doxorubicin


[Fig. 7]


Normal
Tumor


[Fig. 8]


Normal
Tumor
H score
350
300
250
200
150
100
50
0
0
10
20
30
40
50


[Fig. 9]


(p=7.123E-14)
H score
300
250
200
150
100
50
0
Normal
Tumor


[Fig. 10]


shRNA NC RIP3
RIP3
actin
HT-29
HT-29
shNC
shRIP3-2
shRIP3-3
Cell viability (%)
120
100
80
60
40
20
0
0
2.5
5
50
100
(μM)
Doxorubicin
Etoposide

[Fig. 11]


shRNA NC RIP3
RIP3
actin
T47D
T47D shNC
T47D shRIP3
Cell viability (%)
120
100
80
60
40
20
0
0
2.5
5
50
100
80
Doxo (μM)
Etopo (μM)
Taxol (ng/mL)

[Fig. 12]


RIPK3
Kaplan-Meier survival estimates for pool
p<0.0085
Probability of MR-free survival
1.0
0.8
0.6
0.4
0.2
0.0
RIPK3 > median
RIPK3 < median
HR 0.74; 95% CI:0.60 - 0.93 > median
p value 0.0085
0
2
4
6
8
10
Time (years)
Patients at risk:
582 507 429 305 189 93
584 486 403 300 203 112